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Abstract
After briefly reviewing the nature of DNA methylation, its general role in
cancer and the tools available to interrogate it, we consider the literature
surrounding DNA methylation as relating to prostate cancer. Specific con-
sideration is given to recurrent alterations. A list of frequently reported
genes is synthesised from seventeen studies that have reported on methyla-
tion changes in malignant prostate tissue, and we chart the timing of those
changes in the diseases history through amalgamation of several previously
published data sets.
We also review associations with genetic alterations and hormone sig-
nalling, before the practicalities of investigating prostate cancer methylation
using cell lines are assessed. We conclude by outlining the interplay between
DNA methylation and prostate cancer metabolism and their regulation by
Androgen Receptor, with a specific discussion of the mitochondria and their
associations with DNA methylation.
Highlights
• Many DNA methylation changes are observed between benign and can-
cerous prostate tissue.
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• DNA methylation changes are frequently early and recurrent, suggest-
ing a functional role.
• Androgen-driven metabolic processes in the prostate impinge on DNA
methylation.
• Prostate cancer cell lines offer a good model for some methylation
changes, but not all.
• Clinical/genomic associations have been reported, but multi-region sam-
pling studies are needed.
Keywords: Prostate cancer, Epigenetic, Methylation, Biomarkers,
Metabolism, Mitochondria
1. Introduction: Why consider the epigenome?1
1.1. The origins of prostate cancer are not obviously genomic2
Cancer genomics studies have identified recurrently mutated genes and3
mutation hotspots in a number of cancer types. However, such studies in4
prostate adenocarcinomas have identified no genes recurrently mutated in5
more than a seventh of cases [1]. Studies of locally advanced and metastatic6
prostate cancer have revealed extensive intratumoural clonal heterogeneity7
[2, 3, 4, 5, 6], in some cases revealing clones with distinct genomic origins8
[3, 5]. This extensive clonal and spatial heterogeneity creates a significant9
sampling problem for studies that rely on the use of single tumour specimens.10
In such studies, intratumoural heterogeneity will amplify intertumoural het-11
erogeneity, contributing to the low recurrence rates of genes affected by point12
mutations in prostate cancer [1].13
Other mutation types have higher levels of recurrence, e.g. 8p deletions14
(in 40% of cases) and TMPRSS2-ERG fusions (in 50% of cases) [7, 8], sug-15
gesting that these may be early or convergent events in prostate tumouri-16
genesis. However, many prostate tumours have no definitive genomic driver17
event [1]. This is consistent with the existence of events that precede the18
first somatic point mutations and possibly also the acquisition of the first19
copy number and structural variants. Epigenomic changes are among the20
candidates for early events. Of these, DNA methylation changes have been21
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widely studied and found to be the most recurrent events in both locally22
advanced and metastatic prostate tumours [9, 10].23
In prostate cancer, recurrent genome-wide and locus specific DNA methy-24
lation alterations have been known for decades [11, 12] and these events25
impact on gene expression potential [12, 13]. The high recurrence rates of26
specific somatic alterations in DNA methylation support a strong selective27
pressure for these events and implicate them in the development of neoplastic28
phenotypes and as rate limiting steps in disease evolution [12, 13]. Cytosine29
methylation is the most widely studied epigenetic marker in cancer due to30
the development of quantitative genomics methods that are compatible with31
tissue samples obtained from surgical specimens. To date most studies have32
used prostate cancer cell lines when profiling chromatin structures and hi-33
stone modifications [14, 15, 16] and other variants of cytosine modification34
have only been assessed at a global level in primary prostate cancer tissue35
[17]. Therefore for the purposes of this review we will restrict our focus to the36
wealth of studies that have profiled cytosine methylation in prostate cancer.37
1.2. Considerations for DNA methylation profiling in prostate cancer38
DNA methylation is a stable, heritable genome modification that can39
provide insights into a tumour’s origins and evolution. Methylation profiling40
is aided by the number of well-developed techniques and analysis methods41
available. It is aided also by the requirement only for standard preparation42
of genomic DNA as input, making it applicable to routine tumour tissue43
collections (i.e. in contrast to methods that require cross-linked chromatin).44
A range of methylation profiling methods have been developed, from cis-45
linked, base-pair resolution bisulfite sequencing of the whole genome (WGBS46
[18]) or GC-base enriched regions (eRRBS [19, 20]), to array based averaging47
of methylation at specific CpG sites [21, 22], to locus-averaging methods that48
identify methylation ‘peaks’ (me-DIP [23, 24]) or that may be a proxy for49
functional methylation changes (e.g. MBD pull-down [25, 26]). The most50
widely used platform for studies of clinical tissue samples is the Infinium51
450k array [21], that continues to be used due to its reproducibility, well52
developed analysis methods and consequent potential for integration with a53
wealth of published data from this platform [27, 28].54
Sequencing methods provide the highest resolution profiles and cis-linkage55
information about the status of adjacent CpGs on the same strand, but have56
the largest analytical burden. Standard bisulfite sequencing methods do not,57
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however, discriminate between methyl-cytosine (5-mC) and hydroxy-methyl-58
cytosine (5-hmC), although these marks are believed to have different func-59
tional consequences. To discriminate 5-hmC and 5-mC a two stage analysis60
is required comparing the results of bisulfite sequencing (for a combined 5-61
hmC and 5-mC signal) and oxidative bisulfite sequencing (for 5-hmC alone),62
followed by subtractive analysis. Alternatively, me-DIP approaches using63
5-hmC and 5-mC specific antibodies can also discriminate these signals to64
provide locus-averaged signals. Future improvements in sequencing yields65
and sensitivities for single molecule sequencing platforms may provide differ-66
ent insights into the epigenetic landscape, for example long read technologies67
may allow better phasing of epigenetic states along chromosome domains.68
Recent reports suggest that nanopore-based sequencing technologies may be69
able directly to read the 5-mc or 5-hmc modifications of cytosine [29].70
The DNA methylation landscape varies across the genome, generally71
showing higher methylation at repeat sequences and retrotransposons com-72
pared to lower methylation at active gene promoters and CpG-islands [18, 30].73
High levels of DNA methylation at gene promoter regions (and around the74
transcription start site) correlates with low gene expression [12, 18]. Within a75
gene locus the methylation profile can vary widely (Figure 1A), meaning that76
comparisons between samples (i.e. differential analysis) must rely on either77
comparisons of individual CpG sites or by defining local methylation domains78
(e.g. differentially methylated regions, DMRs) [31]. CpG-islands have low79
DNA methylation variance in cancer, while adjacent regions (termed CpG-80
shelves and CpG-shores; Figure 1B) tend to show higher variation. Most81
recently locally disordered methylation or epipolymorphisms have been re-82
ported [32, 33] and linked to evolutionary plasticity in cancer, as previously83
suggested for epigenetic variation [34, 35, 33].84
The selection of samples for cancer genome sequencing is usually simple85
because the aim is to identify somatically acquired changes (e.g. comparing86
tumour tissue with a germline control sample - often blood or buccal swabs).87
However, tissue specific methylation profiles mean that the most appropriate88
control sample for cancer methylome studies is normal tissue from the same89
organ. More stringently, one might aim to match the proportions of cell types90
(e.g. epithelial, stromal, immune) in the tumour and normal tissue samples.91
In many cancer types (including prostate cancer) a ‘field-effect’ change has92
been observed in the tumour adjacent normal tissue, consistent with a pre-93
neoplastic state. Therefore, depending on the study aims it may be most94
appropriate to compare epigenetic state between tumours, tumour adjacent95
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normal tissue and age-matched tumour-free normal tissue.96
1.3. The data used in this review97
Through this review we will illustrate key points using previously pub-98
lished data sets. For ease of comparison, and due to their greater number, we99
will focus solely on data generated using the Illumina Infinium HumanMethy-100
lation450 BeadChip. For individual genes, and to relate methylation levels101
to gene expression we will use the ‘TCGA’ prostate adenocarcinoma data102
[28], interrogated and plotted using the TCGA Wanderer interface [36]. For103
consistency we use Wanderer’s associations of probes to genes throughout,104
although this naturally leads to probes mapping to multiple genes.105
For the second data set, the ‘Tissue’ data set, we amalgamate data from106
several sources [26, 37, 27, 38, 39] to obtain methylation statuses for prostates107
from men with no prostate cancer (“Normal”), morphologically normal tis-108
sue from men with prostate cancer (“Benign”), benign prostatic hyperpla-109
sia (“Hyperplasia”), neoplastic tissue (“Neoplasia”), primary tumours (“Tu-110
mour”) and metastases (“Metastasis”). We also obtain blood profiles [39] as111
an additional reference.112
For Figure 3A, where space is a constraint, we use only a subset of these113
drawn from two sources [26, 37]. The third data set, the ‘Cell line’ data114
set consists of the combined HumanMethylation450 data detailed later in115
Table 1. Finally, to annotate genes with androgen receptor (AR) regulation116
data, we use two previously-published androgen-treated cell line time-course117
data sets [40, 39].118
2. Recurrent epigenetic changes in prostate cancer: markers and119
drivers of disease evolution120
Recurrent alterations in DNA methylation at the GSTP1 gene promoter121
and concomitant loss of GSTP1 expression in prostate tumours were reported122
over 20 years ago [12]. This finding has been replicated in countless indepen-123
dent studies (for example [9, 41, 42]) and well over 1000 samples (reviewed124
in [43]), providing strong evidence that DNA methylation changes are indeed125
recurrent across patient cohorts and could be useful markers for the clinical126
detection of prostate cancer [9, 44].127
Several other genes have also been reported to be recurrently hyperme-128
thylated in prostate cancer by multiple studies Synthesizing data from 17129
studies [26, 45, 27, 28, 10, 46, 2, 47, 48, 20, 24, 49, 38, 22, 50, 51, 52], we130
5
identify 861 genes that are reported in two or more studies, 168 in three or131
more (detailed in Supplementary Table 1 and Supplementary Figure 1), and132
45 that are reported in four or more studies (Figure 2). Some gene families133
are also recurrently affected, consistent with functional convergence, includ-134
ing multiple changes at the HOX gene family loci (Figure 2, Supplementary135
Figure 1) [10, 49].136
2.1. Early epigenetic changes in prostate carcinogenesis137
The high recurrence rates of these DNA methylation changes suggest138
that they may be early events in tumourigenesis. Indeed several studies139
have detected many such methylation changes in neoplastic samples (PIN)140
and tumour adjacent, morphologically benign tissue [53, 54, 27]. Indeed141
the majority of loci that have been suggested as differentiating benign and142
cancerous prostate appear already to have undergone epigenetic changes in143
neoplastic tissue (Figure 2) impacting on their potential as prostate cancer144
markers, but highlighting early or shared events in cancer evolution.145
Prospective multi-region sampling studies with good clinical annotations146
are therefore needed to map tumour specific markers comprehensively, in147
order to improve diagnostic accuracy from tissue biopsies and non-invasive148
monitoring. Given the current over-treatment of primary prostate cancer149
it is also imperative that robust panels of markers are developed to allow150
patient stratification for active surveillance or clinical intervention.151
2.2. An epigenetic ‘field-effect’ in cancerous prostates152
Recent studies suggest that DNA methylation changes in tumour adjacent153
‘normal’ tissue may reflect a ‘field effect’ in cancerous prostates [50, 24, 27].154
DNA methylation profiles have been reported to differ between tumour adja-155
cent benign tissue and benign tissue from cancer-free prostates [50, 24], while156
benign samples taken at different distances from prostate tumours show sim-157
ilar profiles, supporting a wide clonal expansion of morphologically normal158
cells [50].159
This observation is consistent with the outgrowth of tumour clones orig-160
inating from clonal benign and PIN tissue, a concept supported by a recent161
study comparing multiple benign, neoplasia and tumour samples from the162
same cancerous prostates [27]. In this study a common phylogenetic ‘trunk’163
could be identified using either copy number or DNA methylation profiles,164
linking tumour samples, PIN and adjacent normal prostate samples. This in-165
dication of a shared clonal ancestry contrasts with the more sparse data from166
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genome sequencing studies, where few point mutations, indels or structural167
variants link separate tumour foci and pre-cancerous tissues [5], suggesting168
that the expansion of genetically mutated clones is a later event than the169
expansion of clones harbouring DNA methylation alterations.170
Further studies are required to define more clearly the early neoplastic171
and tumour initiating events and also comprehensively to distinguish early172
events from convergent evolution. Longitudinal monitoring through the life-173
history of a patient with prostate cancer would be required to give a definitive174
answer to these questions, although this would be very difficult to achieve.175
An alternative approach would be to combine multi-region tissue sampling176
cohorts with base-pair resolution methylation sequencing to distinguish early177
events from convergent evolution. Understanding this would impact on the178
utility of these changes both as markers of early tumourigenesis and as targets179
for preventative medicine.180
2.3. Underlying clonal stability and ongoing epigenetic evolution in prostate181
tumours182
GSTP1 methylation is present at all stages of prostate cancer devel-183
opment [51], showing that specific epigenetic changes can be maintained184
throughout disease evolution. In addition, methylome-wide studies have185
shown stable epigenetic profiles between metastatic deposits within a patient186
[26] and clear evidence of shared origins for metastatic deposits in primary187
tumours and premalignant lesions [27]. Interestingly, in most cases neoplastic188
lesions (PIN) were evolutionarily more similar to localized tumour samples,189
whereas metastatic deposits were often more closely related to a separate190
subset of localized tumour samples [27].191
Hypomethylation of repeat sequences and cancer testes antigens have192
been suggested to be relatively late events in prostate cancer development193
[55, 30]. In addition, metastatic sites have been reported to show greater194
divergence for DNA hypomethylation within some patients [30].195
Studies showing clonal stability of DNA hypermethylation, and evidence196
of a subset of clones that are more closely related to metastatic disease, sup-197
port the idea of using DNA methylation markers for prostate cancer detection198
and prognosis.199
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2.4. DNA methylation markers for the detection and stratification of prostate200
cancer201
Combined panels of candidate DNA methylation markers have been shown202
to have high sensitivity and specificity for the discrimination of prostate can-203
cers from benign tissue [51, 38], with more recent studies showing proof of204
principle in prostate biopsy material [38]. Several studies have shown the po-205
tential for non-invasive monitoring of DNA methylation in cell-free DNA to206
detect prostate cancer [56, 57, 58, 59]. Many of these studies show remark-207
able sensitivity and support the use of these tests for monitoring disease208
progression, however larger studies will be required to determine the clinical209
utility of these promising tests for prostate cancer diagnosis.210
A molecular stratification for prostate cancer was proposed recently [28].211
This large study found associations between genomic alterations and epi-212
genetic profiles, that may represent a phenotypic difference between these213
molecular subtypes of prostate cancer. One third of ERG-positive tumours214
clustered together with a distinct hypermethylation profile [28]. The one215
percent of prostate cancers that harbour mutations in the gene encoding216
isocitrate dehydrogenase (IDH1) were found to have a divergent genome-wide217
hypermethylation profile [28]. This is likely to be a result of IDH1-R132H mu-218
tations driving production of the oncometabolite 2-hydroxyglutarate (2HG),219
with a reciprocal decrease in alpha-ketoglutarate, a key component in the220
metabolic pathways of DNA methylation (the upstream metabolic processes221
are described in Section 3). It is currently unclear whether these molecu-222
lar subtypes have clinical utility, what other factors impact on the observed223
methylation profiles, or what the phenotypic consequences of these epigenetic224
differences might be.225
More effective diagnosis of prostate cancer would alleviate some of the cur-226
rent burden on health systems and decrease invasive procedures on healthy227
men. However, it is also critically important to distinguish indolent from228
aggressive prostate cancers so that aggressive treatments can be appropri-229
ately allocated to those patients who require such interventions, sparing other230
patients unnecessary over-treatment. Associations between DNA methyla-231
tion changes and prognosis have been reported, including the correlation of232
PTGS2 (COX-2 ), HOXD3 and ABHD9 hypermethylation with recurrence233
[51, 22].234
One study aiming to identify prognostic methylation markers for prostate235
cancer highlighted over one hundred candidate genomic loci [49]. However,236
the discrimination between relapsed and non-relapsed samples was far weaker237
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than between tumour and benign samples [49], indicating more subtle dif-238
ferences between these groups. Among the candidate prognostic markers239
only PTGS2 (COX-2 ) was validated from the previously mentioned studies.240
However, other studies have reported more promising findings by combining241
pilot genome-wide screening with targeted approaches on large test and vali-242
dation cohorts [60]. A three gene methylation signature (AOX1, C1ORF114,243
HAPLN3 ) was able to predict biochemical recurrence with respective hazard244
ratios of 1.9 and 2.3 in test and independent validation cohorts [60].245
By taking a different approach and examining morphologically normal246
tissue adjacent to tumours, the methylation status of GSTP1 and APC has247
been reported to have prognostic utility [61]. GSTP1 and APC methylation248
in tumour adjacent tissue correlated with the methylation of these loci in249
matched tumour samples [61], consistent with either shared clonal ancestry250
or convergent evolution. Either hypothesis to explain these DNA methylation251
changes in tumour adjacent tissue would support a field-effect in a subset of252
prostate cancers that may impact on outcome. These results are consistent253
with other reports of an epigenetic field effect (summarized in Section 2.2)254
and confirm other reports that epigenetic profiling could be a useful tool to255
avoid false-negatives in diagnostic biopsies [62].256
In addition to these important targeted studies in large cohorts there is a257
need for methylation profiling studies that implement sensitive, genome-wide258
methods across samples representing the full range of prostate cancer disease259
stages to provide a clearer picture of the likely diagnostic and prognostic260
utility of these and other DNA methylation markers for prostate cancer.261
2.5. Epigenetic regulation of alternative promoter usage in prostate cancer262
In addition to gene silencing, DNA methylation can modulate gene iso-263
form expression by impacting on alternative promoter regions. For example264
DNA methylation at the RASSF1, APC and NDRG2 loci were shown to265
result in differential isoform expression [46]. This isoform selective expres-266
sion was actively enforced by the epigenetic status at these loci, as shown by267
reversal of the isoform expression profile upon treatment with the demethy-268
lating agent 5-aza-cytidine [46]. Similar events have been reported in other269
studies in prostate cancer [63], however the true extent of this feature will270
only be made clear by large cohort studies combining comprehensive methy-271
lation profiling with RNA-sequencing on the same samples. An exemplar272
study leveraged the large RNA-sequencing gene expression data sets gener-273
ated by TCGA groups to identify isoform switching in multiple tumour types274
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(including prostate cancer), and speculate that epigenetic factors could be275
responsible [64]. In this study, tumour samples could be accurately identified276
solely by isoform switching signatures, highlighting the potential for isoform277
switching as a marker for prostate cancer.278
2.6. Associations between epigenetic and genetic alterations in prostate can-279
cer280
Given the early and recurrent acquisition of GSTP1 hypermethylation281
in prostate tumourigenesis many studies have suggested a role for GSTP1282
silencing in driving disease evolution by increasing the mutation rate [65,283
66, 67, 68]. Recent studies integrating methylation profiling with genome284
sequencing have uncovered additional associations between the epigenetic285
and genetic changes in prostate cancer.286
Firstly, it has been shown that the methylation levels in matched benign287
samples are increased at mutated CpG sites in the tumour in comparison288
to non-mutated CpGs. [20]. This is consistent with the hypothesis that289
methylated cytosines are deaminated to uricil (and subsequently copied as290
thymine), a process believed to drive the observed high C-to-T mutation291
rates observed in prostate and other cancer types [69, 5].292
More surprisingly, it has been reported that sites of tandem duplication293
events in prostate cancer are frequently hypomethylated, while interchromo-294
somal translocation break points are frequently hypermethylated [20]. These295
intriguing observations will need to be investigated in larger cohorts with296
paired methylome sequencing and genome sequencing to better characterize297
these associations.298
Several studies have also suggested a link between ETS gene fusion status299
and DNA methylation profiles [46, 45, 48, 28]. LINE repeats show differen-300
tial methylation between ERG-positive and ERG-negative prostate tumours301
[46], differentially methylated regions associated with ERG status have been302
identified [48] and alternative mechanisms for EZH2 activation have been303
proposed in ERG-negative tumours to phenocopy at least some of the con-304
sequences of ETS gene fusions [45]. The implications of molecular subtype305
differences in DNA methylation profiles are significant. Differences between306
ETS -fusion positive and negative cases highlight the interplay between epi-307
geneic state, gene rearrangements and hormone signalling, since the AR regu-308
lates ETS -fusions and AR signalling is altered in ETS-positive tumours [15].309
Equally, these effects could lead to misinterpretation of studies that cannot310
take them into account.311
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2.7. Epigenetic changes impacting on hormone signalling in prostate cancer312
In addition to interactions with genomic events, the epigenetic profile313
has been linked to AR signalling, both as a modulator of hormone response314
and a driver event in progression to Castration Resistant Prostate Cancer315
(CRPC). AR-bound enhancers were observed to show greater intratumoural316
DNA methylation variation than other enhancer sites [27], suggesting clonal317
plasticity in the AR regulome.318
An integrative analysis of copy number and DNA methylation in CRPC319
revealed convergence on the androgen synthesis pathway, with copy number320
and methylation changes converging on HSD17B2 and other targets that321
may be involved in hormone therapy resistance [10].322
Loss of AR protein expression is a characteristic of hormone-relapsed323
Prostate Cancer (PCa) that is no longer dependant on AR signalling, a phe-324
notype that is becoming more common following the clinical use of second325
generation AR targeting therapies [70, 71]. Epigenetic silencing of AR gene326
expression has been reported in prostate tumour samples [72, 73] and treat-327
ment of AR negative PCa cells with the global demethylating agent 5-aza-328
deoxycytadine can induce functional AR signalling in these cells [73, 74, 75,329
76]. However, other studies in CRPC have reported no change in AR pro-330
moter methylation [10], suggesting either differences between analysis meth-331
ods or possibly patient cohorts treated with different hormone therapies.332
Combining androgen signalling blockade with the demethylating agent333
5-aza-deoxycytadine increased response in the preclinical models of PCa334
[77, 75], suggesting that future studies combining demethylating agents with335
second generation AR blockade may improve patient outcome or delay re-336
lapse by targeting the AR, its target genes or upstream pathways.337
Oestrogen receptor alpha and beta methylation have also been identi-338
fied in some studies of prostate cancer samples [78, 51, 46, 26]. Although339
these methylation changes at ER genes are not highlighted in the major-340
ity of studies it is noteworthy that studies reporting ER gene methylation341
used MSP [51], MBD-pulldown [26] or restriction enzyme based methods [46]342
(consistent with either limitations of the more commonly used 450k arrays343
at these loci or convergent artefacts between the other methods). Future344
studies should aim to assay DNA methylation at the ERS1 and ESR2 loci345
in prostate tissues to determine whether this could affect the interplay be-346
tween nuclear hormone receptors and be another mechanism through which347
epigenetic changes impact on hormone signalling in prostate cancer.348
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A large number of these putative epigenetic markers were identified by349
methylation profiling of prostate cancer cell lines. In addition these cell line350
models are the most widely used tools for functional validation studies of351
candidate gene silencing or de-repression events identified from genome-wide352
profiling studies. Therefore we summarize the utility and limitations of these353
models below.354
2.8. Prostate Cancer Cell lines355
It has for some time been recognized that immortalized cell lines do not,356
in respect of their methylation patterns, reflect the cells from which they orig-357
inate; typically immortalized cells exhibit hypermethylation of CpG islands358
[79, 80, 81] although it has been noted that this may represent selection359
pressure where highly methylated cells are more likely to be immortalized360
successfully [82] and there are suggestions that the methylation changes can361
predate immortalization [83].362
The characteristic methylation changes that occur in immortalized cells363
are similar to the changes seen in cancers [84, 85] raising the hope that364
the epigenetics of cancer cell lines may represent malignant tissue well. Re-365
cent reports argue that it is specifically the immortalization of cells rather366
than other oncogenic activity that leads to changes in methylation profile367
[86]. Intriguingly, sites that are methylated in cancer cell lines are enriched368
for NANOG binding sites [87]. As well as its role in maintaining stem cell369
pluripotency, NANOG has been shown to be pro-tumourigenic in prostate370
cancer cell lines, conferring cancer-stem-cell-like properties [88], and is di-371
rectly androgen regulated [89].372
Early targeted studies identified good agreement between primary cancers373
and cell lines [90, 91], but broader differences may mean that only a minority374
of tumours are well-represented by cell lines. Genome-wide profiling has375
revealed xenografts to be a better model in head-and-neck squamous cell376
carcinomas [92], while a recent paper has reported near-complete loss of 5-377
hydroxymethylcytosine [93] - raising questions about cell lines’ value in this378
regard.379
The utility of prostate cell lines is further affected by the fact that the380
commonly used prostate cancer cell line models (recently reviewed elsewhere381
[94]) were derived from metastases, and metastasis itself is associated with382
changes in methylation profiles [95, 96]. Nevertheless, substantial public383
data exist for a number of prostate cell lines as denoted in Table 1, notably384
LNCaP, PC3 DU-145 and PrEC, making them an attractive resource.385
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In Figure 3 A, we cluster the available Illumina Infinium HumanMethy-386
lation450 BeadChip cell line data with our example Tissue data set. It is387
notable that inter-sample heterogeneity increases as one progresses through388
normal, benign, tumour and metastasis samples. Reflecting their origins, the389
prostate cancer cell lines are more alike the metastasis samples than they are390
the primary tumour samples, while the PrEC cells cluster with the normal391
samples.392
It should be noted that all of the cell lines show levels of agreement with393
primary tumours that are substantially above chance, and that their greater394
similarity to metastases only requires care to be taken over the interpreta-395
tion of any results arising. The cell lines still reflect the behaviour of primary396
tumours at key loci such as GSTP1 (Figure 3B), although at loci such as the397
promoter of TERT there appears to be progressively greater DNA methyla-398
tion as one moves from normal tissue, through hyperplastic and neoplastic399
tissues to primary tumours and metastases, the malignant cell lines showing400
greater values still (Figure 3C).401
Despite the inevitable caveats about the use of cell lines, they offer natural402
advantages for the inference of function. They enable one to run controlled403
experiments with identical subjects in each/every arm, and make it possible404
to measure multiple characteristics (e.g. genome-wide methylation and tran-405
script abundance) on effectively the same samples. Both of these have been406
exploited to address questions of prostate cancer biology.407
To understand better the methylation-driven regulation of the cancer408
genome, mRNA expression data are the natural orthogonal data to bring into409
an integrative analysis. In this manner, the methylation-regulated nature of410
key genes and alternative transcriptional start site usage have been explored411
in prostate cancer [46, 97].412
A substantial body of work has linked DNA methylation with other epige-413
netic marks better to understand gene regulation in (prostate) cancer. The414
H3K27me3 mark at promoters is associated with inactivated genes, while415
methylation of promoters is similarly associated with gene repression, but416
the two mechanisms have been seen to be neither exclusive nor determinis-417
tically linked in LNCaP [98]. Where the two mechanisms do coexist, a dual418
therapy to reinstate expression of tumour suppressor genes becomes a pos-419
sibility [99]. Elsewhere it has been shown that a genome-wide restructuring420
of nucleosome densities is associated with changes in DNA methylation of421
enhancer regions of PCa cell lines [100].422
Other studies have sought to explain epigenetic mechanisms of treatment423
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and resistance to treatment. Epigenetic silencing of SLFN11 has been asso-424
ciated with resistance to platinum-based chemotherapies in a number of cell425
lines including DU-145 and PC3 [101], an epigenetic mechanism of the pre-426
ventative agents sulforaphane and 3,39-diindolylmethane is elucidated [102],427
and the mechanism of Genistein has been shown not to be dependent on428
broad methylation changes, but rather histone acetylation [103].429
Perhaps most interestingly for our topic, a recent report has shown that430
dosing cells with S-adenosylmethionine (SAM) inhibits invasion [104]; the431
same group having previously identified a role for hypomethylation in the432
metastasis of prostate cancer [105]. SAM is an important methyl donor433
for histone, DNA and RNA methylation, and all general protein lysine and434
arginine methylation (as described in Section 3). The demonstration, in435
vitro and in vivo, that replenishing the reservoir of methyl donors can inhibit436
metastasis (while only increasing the methylation status of specific loci rather437
than reversing the genome-wide hypomethylation) provides some evidence of438
a mechanistic role for the methylation patterns in metastases, highlights the439
importance of the available metabolic pool for cancer progression, and invites440
consideration of the broader role of SAM in the metabolic pathways.441
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Figure 1: A. Average methylation profiles for prostate tumours (n=340) and normal
prostate tissue (n=49) at the GSTP1 gene locus using the TCGA data set (see section 1.3).
B. Schematic showing the GSTP1 gene locus, indicating the location of the CpG-island,
CpG-shore (<2kb from island) and CpG-shelf (2-4kb from island). C. Correlation scatter
plot for GSTP1 expression and methylation (using the 450k array probe highlighted in
panel-A). D. Correlation scatter plot for CDKN2A expression and methylation (using the
450k array probe highlighted in panel-E). E. Average methylation profiles for prostate at
the CDKN2A gene locus using the Prostate TCGA data set (see section 1.3). F. Schematic
showing the gene and CPGI features at the CDKN2A locus.
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Figure 2: Heatmap summary of genes and marker probes associated with DMRs reported
in four or more studies. Left panel, correlations between gene expression (RNA-seq) and
DNA methylation (450k arrays), from the PRAD TCGA data set (450k probe IDs indi-
cated on the left). Middle panel, average methylation levels (Beta-values) from multiple
studies spanning a range of prostate tissue types (450k probes indicated on the right).
Right panel, androgen-stimulated gene expression changes in two prostate cancer cell lines
(autocorrelation values denote a change with time following stimulation - a value of zero
indicates no systematic change after stimulation). Missing data are indicated with a cross
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Figure 3: Cell lines as a representation of primary tumours. A) Clustering of our example
cell line and tissue data sets (described in Section 1.3). The distance between two samples
is defined as Cohen’s Kappa measure of agreement (applied after dichotomizing methy-
lation beta values). B) Illustrating, from the cell line and tissue data sets, the median
proportion of methylation at loci near the GSTP1 promoter. As expected, the cancer cell
lines are generally hypermethylated in this region, as are the neoplastic and malignant
tissues. C) Illustrating, from the cell line and tissue data sets, the median proportion of
methylation at loci near the TERT gene. An area in the gene promoter shows progres-
sively increased methylation levels, with the cancer cell lines levels most in keeping with
metastases.
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3. Effects of the metabolic pool on DNA methylation442
The prostate gland is a metabolically specialized organ responsible for443
supporting sperm viability. This specialization is characterized by net se-444
cretion of citrate into the seminal fluid [106]. Whilst a significant reduc-445
tion in the production of these metabolites has been reported in numerous446
magnetic resonance spectroscopy studies on clinical samples, the molecular447
drivers for this down-regulation remain controversial [107, 108, 109, 110].448
Of the polyamines normally produced by the prostate gland, spermine is449
particularly abundant [111]. Rat models of castration-induced regression450
and testosterone-induced regrowth of the prostate gland have shown that451
polyamine production is tightly regulated by androgens, in part through452
control over the expression of key biosynthetic enzymes (ornithinedecar-453
boxylase (ODC), S-adenosylmethionine decarboxylase (AMD1) and spermi-454
dine synthase (SMS); highlighted in Figure 4 and Figure 5) [112, 113, 114].455
The methyl donor in this pathway is S-Adenosylmethioninamine (decarboxy-456
AdoMet), a metabolite that is directly downstream of the DNA methylation457
donor S-Adenosylmethionine (SAM, AdoMet). Therefore, alterations in the458
flux through either polyamine metabolism or DNA methylation would be ex-459
pected to affect the available pools of methyl-donors, with reciprocal effects460
on the flux of the other pathway.461
The prostate has one of the highest concentrations of polyamines of any462
tissue in the body and the expression of these enzymes is associated with463
glandular epithelial cells with significant quantities of polyamines secreted464
into seminal fluids. Spermine levels in clinical samples have been reported465
to correlate positively with the differentiation status of the tumour and in466
preclinical models to promote growth inhibition [115, 116].467
Polyamine synthesis requires one-carbon metabolism and in particular468
methionine metabolism with S-adenosylmethionine (SAM) which upon de-469
carboxylation acts as the primary aminopropyl donor for polyamine synthe-470
sis (Figure 4) [117]. Consequently the fate of methionine and its deriva-471
tives may be influenced by changes in the specialized secretory functions of472
the prostate gland as cancer emerges, in particular a decline in polyamine473
biosynthesis and secretion may enhance the pool of SAM available to sup-474
port epigenetic modifications (metabolic pathway links shown in Figure 4).475
Proving causative associations between rates of polyamine biosynthesis and476
regulation of the epigenetic state via the availability of SAM is extremely477
challenging, since methylation patterns can be highly locus and cell-type de-478
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pendent and are supported by a complex regulatory network downstream479
of metabolite consumption and upstream of DNA substrates. Furthermore,480
one-carbon metabolism consists of a number of additional interconnected481
metabolic processes that may impinge on polyamines and the epigenome482
(folate cycle, methionine cycle and glycine/serine metabolism, Figure 4).483
Prostate cancer is characterized by the activity of transcription factors,484
particularly AR but also others such as c-Myc. A natural question then485
is how the transcription factors and important enzymes interact with the486
metabolome and epigenetic status of a tumour. As indicated earlier, the487
synthesis of polyamines and the expression of the key enzymes required for488
this and a number of other metabolic processes upstream of SAM produc-489
tion are driven by AR and associated with differentiated prostate cancers490
(Figure 4 and Figure 5).491
Glycine N-methyltransferase (GNMT) is an enzyme which converts glycine492
to sarcosine and in the process converts SAM to S-adenosylhomocysteine493
(Figure 4). In cell-lines expression of the GNMT enzyme is androgen de-494
pendent and in tissue samples it has been shown to be over-expressed in495
prostate cancers (Figure 4 and Figure 5) [118, 40]. Sarcosine, the product of496
the reaction catalysed by GNMT, has also been reported to be elevated and497
detectable in urine samples and some studies have associated this with the498
emergence of castrate-resistant disease [119, 120]. Of the enzymes involved499
in one-carbon metabolism GNMT is therefore currently the most extensively500
characterized androgen-dependent component of the pathway. By contrast501
the expression of enzymes required for serine metabolism appears in prostate502
cancer cell-lines to be repressed by androgens and in other cancer models to503
be induced by c-Myc [40, 121]. Whilst serine metabolism also impacts on504
the methionine cycle, the most direct impact of serine consumption appears505
to be to sustain de novo nucleotide biosynthesis in support of elevated rates506
of DNA replication and/or transcription and cell proliferation[122]. This507
in turn is often a feature of cell cycle dysregulation, characteristic of late-508
stage, metastatic prostate cancer [123]. Hypothetically a phasic transition509
in one-carbon metabolism may therefore consist initially of reduced rates of510
polyamine biosynthesis and enhanced DNA and histone methylation in local-511
ized disease transitioning into enhanced serine metabolism during metastatic512
progression. This would at least be consistent with the observations that513
DNA hypermethylation is an earlier event in prostate tumourigenesis, while514
hypomethylation may occur in later stage disease (as described in Section 2).515
The DNA methylation status of a subset of genes encoding these metabolic516
20
enzymes increases between normal samples compared to benign, tumour and517
metastasis, consistent with early hypermethylation changes (Figure 5). A518
separate set of enzyme-encoding genes show hypomethylation in metastatic519
samples compared to localized and pre-malignant samples (Figure 5), again520
consistent with genome-wide observations of later stage hypomethylation521
(Section 2). It is of interest that there appears to be exclusivity of regu-522
lation within the metabolism-related genes illustrated here (Figure 5), with523
AR-regulated genes showing little evidence of differential methylation, and524
the strongest differentially methylated genes not being AR-regulated. This525
despite the independence of the data sets from which these characteristics526
were identified.527
In addition to the potential influence of upstream enzyme expression and528
metabolite pools on DNA methylation, the de-methylation pathway is in-529
tricately linked to central metabolism. The TCA cycle metabolite alpha-530
ketoglutarate is required for TET enzyme activity, the first step in cytosine531
demethylation (Figure 4). Therefore, mitochondrial function may have a pro-532
found effect on both cytosine methylation and the levels of hydroxymethyla-533
tion in the genome of a cell.534
4. Mitochondrial methylation and prostate cancer535
4.1. Importance of mitochondria in PCa536
While of general interest in cancer (reviewed, for example by Wallace537
[124]), mitochondria are of specific interest in prostate cancer beyond the538
characteristic zinc-inhibition of TCA cycle and AR regulation of certain539
metabolites described in the previous section. Recent ‘pan-cancer’ analy-540
ses have identified many mutations in mitochondrial DNA, without showing541
them to be drivers [125, 126], but animal models have demonstrated the func-542
tional impact of mitochondrial genetic mutations on prostate cancer [127] and543
a cohort study in humans has identified associations with proliferation [3].544
The case for DNA methylation changes in the prostate cancer mitochon-545
dria themselves is not as clear cut as that for genetic changes. Methyla-546
tion of mitochondrial DNA has been controversial since it was first reported547
[128]. Subsequent papers variously confirmed this result [129] or reported no548
such methylation [130]. The discussion has continued since with arguments549
for and against based on sequence analysis [131, 132], and use of methyla-550
tion sensitive and insensitive restriction enzymes [133, 134]. One aspect of551
the argument against the existence of methylation in the mitochondria has552
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Figure 5: Heatmap summary of genes in metabolic pathways that impact on DNA methy-
lation (relating to Figure 4). Left panel, correlations between gene expression (RNA-seq)
and DNA methylation (450k arrays), from the PRAD TCGA data set (450k probe IDs
indicated on the left). Middle panel, average methylation levels (Beta-values) from multi-
ple studies spanning a range of prostate tissue types (450k probes indicated on the right).
Right panel, androgen-stimulated gene expression changes in two prostate cancer cell lines
(autocorrelation values denote a change with time following stimulation).
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been the absence of the actors that facilitate methylation of nuclear DNA.553
However, recent years have seen the identification of methyl donors [135],554
methyltransferases [136, 137], and even TET1 present in the mitochondria555
[138]. This latter observation supporting reports of 5-hydroxymethylcytosine556
in the mitochondrial DNA [136, 139]. The history of this topic is reviewed557
more thoroughly elsewhere [140].558
Recently there have been studies that provide stronger evidence that epi-559
genetic modifications of mitochondrial DNA do indeed take place. For exam-560
ple, one study identified methylated bases in nucleus-free platelets [141], while561
another used orthogonal and complementary technologies to profile the mi-562
tochondrial methylation in a wide range of tissue and cell types [142]. Given563
the unique behaviour of mitochondria in prostate cancer, if mitochondrial564
DNA can be methylated, this is an aspect that may reward investigation.565
4.2. Reciprocal regulation of nuclear methylation and mitochondria566
Apart from direct epigenetic changes to the mtDNA, the mitochondria567
have a complex relationship with epigenetic alterations to the nuclear DNA.568
Of the order of a thousand coding genes have products that are active in569
the mitochondria, and only 13 originate from the mitochondrial DNA. It fol-570
lows that any epigenetic regulation of the remaining mitochondrial actors in571
the nucleus will likely influence mitochondrial behaviour. One study identi-572
fied tissue-specific differentially methylated regions in mitochondrial-acting573
nuclear-encoded genes [143] while another has concluded that epigenetic reg-574
ulation of mitochondrial-acting nuclear-encoded genes was higher than other575
nuclear-encoded genes [144]. This latter result can be replicated in prostate576
cancer using a single tumour sample (Figure 6A). While this is represen-577
tative of the other samples in our example set, with > 5, 000 probes from578
regions around the transcription start sites of mitochondrial actors showing579
consistent hypomethylation and approximately 400 showing consistent hy-580
permethylation, there is also evidence of changes in the regulation of these581
regions with the progression of disease. Figure 6B shows a heatmap of the582
114 most variable probes in these regions, and it is apparent that again there583
are clusters of probes that variously gain methylation in neoplastic tissue584
and continue to do so in tumour and metastases, others with the opposite585
pattern, and smaller numbers where the changes are primarily defined by the586
metastases samples.587
DNA polymerase gamma is responsible for the replication of mitochon-588
drial DNA and is regulated by the methylation of the POLG gene [145, 146]589
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Figure 6: A. Reproducing Figure 4 of Chinnery et al. for a high-cellularity prostate cancer
sample. Probes on the Infinium HumanMethylation450 BeadChip that lay within 1000
bases of transcription start sites (TSS) were divided between genes listed in MitoCarta
and those that are not. B. A heatmap of median beta methylation values for different
tissues across probes that show most variation in our data.
leading to associations between mtDNA copy number and POLG methy-590
lation levels. Methylation of the PPARGC1A gene has also been seen to591
correlate negatively with mtDNA copy number.592
While the methylation of some genes can regulate mtDNA copy number,593
it has also been shown that mtDNA copy number can regulate some nuclear594
genes [147, 144]. Furthermore, studies using cybrids have shown that the595
mitochondria can affect nuclear methylation patterns [139, 148]. Given the596
importance of epigenetics to prostate cancer regulation, and the characteristic597
behaviour of mitochondria (and broader metabolic pathways) in the disease,598
these associations demand attention in attempts to unravel prostate cancer599
biology.600
5. Current perspectives and future directions for the role of epige-601
nomic changes in prostate cancer602
It is clear that clonal expansions of cells with stable epigenomic changes603
occur in prostate cancer. DNA methylation changes are the most recurrent604
events so far identified in prostate cancer, and specific changes may associate605
with outcome. The epigenome continues to evolve throughout the life history606
of prostate cancer, with distinct features presenting at different stages and607
interacting with specific genomic changes. It will be crucial to overlay other608
epigenetic changes within the same cohorts of samples to build up a picture609
25
of the epigenetic landscape in prostate cancer. Future studies are also needed610
to integrate both genomic and epigenomic data in large cohorts of samples, to611
elucidate the interaction between genomic and epigenetic changes, to provide612
a more comprehensive view of the pathways affected in each prostate tumour613
sample, and to assess clinical associations with specific sets of changes.614
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Supplementary Material630
SupplementaryTable1-Genelists.xls631
A spreadsheet summarizing all genes reported in the 17 published studies632
relating to the prostate cancer tissue summary in main text.633
SupplementaryTable2-ReccurentlyCalledGenesAnnotated.xlsx634
For all genes reported in at least three of the 17 studies, we present corre-635
lation with gene expression and median beta methylation values for several636
tissues for the probe showing greatest correlation with expression and the637
probe showing greatest differential methylation. Additionally. autocorrela-638
tions from time-course experiments are used to annotated genes as being AR639
regulated as detailed in the main text.640
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SupplementaryFigure3-ReccurentlyCalledGenesHeatmap.pdf641
A figure equivalent to Figure 2 in the main text, but presenting all genes642
that were reported in at least three of the 17 studies (in contrast to Figure643
2 which presented genes reported in at least four of the studies).644
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